Please login to the form below
vildagliptin
This page shows the latest vildagliptin news and features for those working in and with pharma, biotech and healthcare.
Novartis to make 15 drugs available at $1 a month
Among the drugs to be made available under the scheme are high blood pressure medicine valsartan, tamoxifen for breast cancer and vildagliptin for diabetes.
Latest news
-
AZ sues to block generic saxagliptin from Mylan
world market for DPP4 inhibitors, a class which also includes Merck &Co's market-leading Januvia (sitagliptin), Novartis' Galvus (vildagliptin) and Boehringer Ingelheim/Lilly's Trajenta (linagliptin).
-
Pfizer still number one - just
Meanwhile, Novartis kept the pressure on with solid performances for its own new entrants, including Gilenya (fingolimod) for multiple sclerosis, cancer drugs Afinitor/Votubia (everolimus) and Tasigna (nilotinib) and Galvus (vildagliptin)
-
NICE turns down Afinitor for breast cancer
for leukaemia, Galvus (vildagliptin) for diabetes and blood cancer therapy Jakavi (ruxolitinib).
-
Novartis lifts 2013 guidance on delay to Diovan generics
Gilenya (fingolimod), Afinitor (everolimus) for breast cancer, leukaemia therapy Tasigna (nilotinib) and Galvus (vildagliptin) for diabetes just about offsetting revenue losses to generic competition of some $800m in the quarter.
-
Setback for AZ and BMS as Onglyza flunks cardiovascular trial
vildagliptin). The trial was set up in the wake of new US FDA guidelines in 2009 which required pharma companies to perform cardiovascular outcome studies on new diabetes drugs.
More from news
Approximately 0 fully matching, plus 25 partially matching documents found.
Latest appointments
-
bmore creative hires Kush Rach as new business director
He was a key account manager at the pharma company, where he worked in the diabetes therapeutic area, and was involved in the UK launch of Galvus (vildagliptin) for type 2
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- Roche’s Ocrevus boasts positive long-term data in MS
- Leadership change within Bedrock Group
- Lilly starts large-scale trial of tirzepatide in diabetic heart disease
- Live Webinar: Telemedicine & the Digitization of Medicine post COVID-19
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- OPEN Health’s Learning & Development team have won a Bronze Award at the PM Society Digital Awards 2020
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
